Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion
Before 2 and 4 dose of Remsima mean PUCAI was 11 (0; 0-40) and 2 (0;0-5), respectively.
A total of 56 patients diagnosed as having IBD [44 Crohn’s disease (CD) and 12 colitis ulcerosa (CU)] and treated with anti-TNFα agents (33 received adalilumab, 23 received Remicade) were evaluated by means of serum lipid profile and serum total cholesterol, triglyceride, LDL-c and HDL-c were measured within 1 month before the first dose of anti-TNFα agent and then after six-month periods.
In total, 59 Remicade infusions were administered at home with a median dose of 369 mg (dose range: 300 to 700 mg).
All currently existing anticancer therapies involving TNF are targeted towards the ligand, TNF itself, which includes administration of very high doses of exogenous TNF for melanoma treatment – or use of soluble receptors and/or various forms of TNF antibodies (Remicade, Humira) and a soluble TNF receptor fusion protein (Enbrel) , .
For the treatment of moderately to severely active UC, the recommended dose of Remicade (IFX; Schering-Plough Corporation, Kenilworth, NJ, USA) is 5 mg/kg given as an induction regimen at 0, 2, and 6 weeks, followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter.
Based on earlier studies of TNFα neutralization in mice , we administered the anti-TNFα antibody infliximab (Remicade, Centocor Ortho Biotech, Malvern, PA) by intraperitoneal injection at 10 mg/kg body weight per dose.
Therefore, infusions of infliximab (Remicade, Merck & Co.) were arranged and given as doses of 5 mg/kg at baseline, 2, 6 and 12 weeks.
Remicade is administered by intravenous infusion (IV) in a physician's office; receipt of a single dose takes 2 to 4 hours.
Her gastroenterologist indicated treatment with 3 doses of infliximab (5 mg/kg/day, Remicade, Schering-Plough, Kenilworth, NJ), but ocular signs did not improve.